Home » Stocks » SGMT

Sagimet Biosciences, Inc. (SGMT)

Sagimet Biosciences will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Market Cap n/a
Revenue (ttm) n/a
Net Income (ttm) -11.37M
Shares Out n/a
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day n/a
Last Price n/a
Previous Close n/a
Change ($) n/a
Change (%) n/a
Day's Open n/a
Day's Range n/a
Day's Volume n/a
52-Week Range n/a

News

Sagimet Biosciences, Inc. has filed to go public with an IPO on the NASDAQ.

4 weeks ago - SEC

About SGMT

Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing a portfolio of internally-discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of several diseases that result from the overproduction of the fatty acid, palmitate. Based on our clinical and preclinical data, we believe that our wholly-owned pipeline of oral FASN inhibitors has the potential to offer treatments for indications in several therapeutic areas of high unmet medical need including liver diseases and cancers. TVB-2640, whic... [Read more...]

Industry
Pharmaceutical Preparations
IPO Date
Pending
CEO
George Kemble, Ph.D.
Employees
5
Stock Exchange
NASDAQ
Ticker Symbol
SGMT
Full Company Profile

Financial Performance

Financial Statements